share_log

Cybin | 6-K/A: Report of foreign private issuer (related to financial reporting)

SEC announcement ·  Feb 15 11:12
Summary by Moomoo AI
Cybin Inc., a biopharmaceutical company listed as CYBN on the NYSE American LLC, filed an amended report with the U.S. Securities and Exchange Commission (SEC) on February 15, 2024. The amendment, Form 6-K/A, was submitted to incorporate Exhibits 99.1 and 99.2 into the company's Registration Statement on Form F-10. This amendment does not change the original report filed on February 14, 2024, except for the specified exhibits. Cybin's interim consolidated financial statements for the nine months ended December 31, 2023, show a significant increase in total assets, from CAD 53.9 million to CAD 129.7 million, and an increase in shareholders' equity from CAD 48.2 million to CAD 121.2 million. The company reported a net loss of CAD 56.7 million for the nine-month period, compared to CAD 33.8 million in...Show More
Cybin Inc., a biopharmaceutical company listed as CYBN on the NYSE American LLC, filed an amended report with the U.S. Securities and Exchange Commission (SEC) on February 15, 2024. The amendment, Form 6-K/A, was submitted to incorporate Exhibits 99.1 and 99.2 into the company's Registration Statement on Form F-10. This amendment does not change the original report filed on February 14, 2024, except for the specified exhibits. Cybin's interim consolidated financial statements for the nine months ended December 31, 2023, show a significant increase in total assets, from CAD 53.9 million to CAD 129.7 million, and an increase in shareholders' equity from CAD 48.2 million to CAD 121.2 million. The company reported a net loss of CAD 56.7 million for the nine-month period, compared to CAD 33.8 million in the previous year. The financial statements also highlight the acquisition of Small Pharma Inc., which became a wholly-owned subsidiary of Cybin on October 23, 2023. The acquisition resulted in an increase in goodwill and intangible assets on Cybin's balance sheet. Cybin's CEO, Doug Drysdale, signed the report, indicating the company's commitment to advancing psychedelic-based therapies for psychiatric and neurological conditions.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

Doc 6

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more